A Phase II, Open Label, Randomized Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following VEGF-Targeted Therapy.

Trial Profile

A Phase II, Open Label, Randomized Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following VEGF-Targeted Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Apitolisib (Primary) ; Everolimus
  • Indications Renal cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ROVER
  • Sponsors Genentech
  • Most Recent Events

    • 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 May 2014 Status changed from active, no longer recruiting to recruiting, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top